MISOPROSTOL FOR TREATMENT OF FETAL DEATH AT 14-28 WEEKS PHASE III
米索前列醇治疗 14-28 周胎儿死亡的第三阶段
基本信息
- 批准号:7213039
- 负责人:
- 金额:$ 21.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
The proposed project is a Phase 3 trial of the drug misoprostol for the treatment of fetal death at 14 to 28 weeks of pregnancy, inclusive. In cases of fetal death this late in pregnancy, it is necessary to clear the uterus of products of conception to avoid serious complications such as generalized coagulopathies. Usually, however, uterine evacuation does not occur spontaneously. Treatments that have been used for this condition previously include dilatation and evacuation surgery, administration of intravenous oxytocin, and administration of prostaglandin E2 suppositories. In recent years, however, most physicians appear to have adopted the practice of administering misoprostol, a prostaglandin E1 analogue, to induce uterine contractions in those patients who do not wish to have a surgical evacuation, or whose pregnancies are so far advanced that surgical evacuation is not possible. Misoprostol has become popular because it is easier to store, is much less expensive, is more effective, and produces fewer side effects than other available treatments.
Although misoprostol is, in most places, the treatment of choice for this indication, no large, rigorous study has ever been conducted to determine the most effective dosing regimen for misoprostol in the treatment of fetal death. This study is a randomized, blinded trial of two different doses of misoprostol (100 micrograms versus 200 micrograms administered every 12 hours) administered via the buccal route. The buccal route of administration has been determined to have the best combination of effectiveness, low side effects, patient acceptability, and conformity with misoprostol's current FDA registration. The proposed research will supply data towards establishing a safe minimum effective dose of drug for this indication, with the ultimate goal of formal FDA approval of the treatment.
The anticipated public health benefit of this study is that it will help systematize what is currently a chaotic, random use of misoprostol for the treatment of mid-term fetal death. This study will provide, among other things, a lowest effective dose of the drug. Women with this condition need treatment. Misoprostol appears to be a superior treatment to current available treatment regimens. What is lacking is data on how best to use misoprostol for this indication. This study is intended to provide the best treatment regimen for the use of misoprostol for this indication.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BEVERLY WINIKOFF其他文献
BEVERLY WINIKOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BEVERLY WINIKOFF', 18)}}的其他基金
MISOPROSTOL FOR TREATMENT OF FETAL DEATH AT 14-28 WEEKS PHASE III
米索前列醇治疗 14-28 周胎儿死亡的第三阶段
- 批准号:
7391830 - 财政年份:2007
- 资助金额:
$ 21.38万 - 项目类别:
相似海外基金
Defining the role of macrophages in fetal lung underdevelopment and the immunomodulatory effects of stem cell extracellular vesicle treatment
定义巨噬细胞在胎儿肺发育不良中的作用以及干细胞胞外囊泡治疗的免疫调节作用
- 批准号:
473703 - 财政年份:2022
- 资助金额:
$ 21.38万 - 项目类别:
Fellowship Programs
Development of a breast cancer preventive treatment targeting the nutritional environment of fetal stage
针对胎儿期营养环境开发乳腺癌预防治疗
- 批准号:
22K07152 - 财政年份:2022
- 资助金额:
$ 21.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Community-based fetal ultrasound and care navigation: An approach to engaging pregnant women with substance use disorder in prenatal care and substance use treatment
基于社区的胎儿超声和护理导航:一种让患有物质使用障碍的孕妇参与产前护理和物质使用治疗的方法
- 批准号:
10649029 - 财政年份:2022
- 资助金额:
$ 21.38万 - 项目类别:
Community-based fetal ultrasound and care navigation: An approach to engaging pregnant women with substance use disorder in prenatal care and substance use treatment
基于社区的胎儿超声和护理导航:一种让患有物质使用障碍的孕妇参与产前护理和物质使用治疗的方法
- 批准号:
10709656 - 财政年份:2022
- 资助金额:
$ 21.38万 - 项目类别:
Candidate Drugs Exploration for Congenital Diaphragmatic Hernia Fetal Treatment
先天性膈疝胎儿治疗候选药物探索
- 批准号:
21K08592 - 财政年份:2021
- 资助金额:
$ 21.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease
调节胎儿血红蛋白治疗镰状细胞病的细胞信号通路
- 批准号:
10592428 - 财政年份:2021
- 资助金额:
$ 21.38万 - 项目类别:
Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease
调节胎儿血红蛋白治疗镰状细胞病的细胞信号通路
- 批准号:
10424557 - 财政年份:2021
- 资助金额:
$ 21.38万 - 项目类别:
Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease
调节胎儿血红蛋白治疗镰状细胞病的细胞信号通路
- 批准号:
10282012 - 财政年份:2021
- 资助金额:
$ 21.38万 - 项目类别:
Development of new fetal treatment by intra-tracheal administration of exosome using an animal model of diaphragmatic hernia
使用膈疝动物模型气管内给予外泌体开发新的胎儿治疗方法
- 批准号:
20K22959 - 财政年份:2020
- 资助金额:
$ 21.38万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Extracellular vesicles derived from amniotic fluid stem cells as a novel treatment strategy to rescue fetal lung underdevelopment
羊水干细胞衍生的细胞外囊泡作为拯救胎儿肺部发育不良的新治疗策略
- 批准号:
435462 - 财政年份:2020
- 资助金额:
$ 21.38万 - 项目类别:
Operating Grants